Evelin Poolamets Pharmaceutical drug Pharmaceutical compound Lifastuzumab vedotin (INN;[1] development code DNIB0600A) is an experimental monoclonal antibody-drug conjugate designed for the treatment of cancer.[2] This drug was developed by Genentech/Roche. References ^ World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 110" (PDF). WHO Drug Information. 27 (4). ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Lifastuzumab Vedotin, American Medical Association. Monoclonal antibodies for tumorsTumorHuman Adecatumumab§ Amivantamab Ascrinvacumab§ Atezolizumab (+hyaluronidase) Balstilimab† Botensilimab Cixutumumab§ Conatumumab§ Cosibelimab Daratumumab Drozitumab§ Duligotumab§ Dusigitumab§ Enfortumab vedotin Enoticumab§ Figitumumab§ Flanvotumab§ Ganitumab† Glembatumumab vedotin† Intetumumab§ Ipilimumab Iratumumab§ Istiratumab Icrucumab§ Lexatumumab§ Lucatumumab§ Mapatumumab§ Narnatumab§ Necitumumab Nesvacumab§ Nivolumab# (+hyaluronidase, +relatlimab) Ofatumumab Olaratumab† Panitumumab Patritumab§ Pembrolizumab# Pritumumab§ Radretumab§ Ramucirumab Rilotumumab† Robatumumab§ Seribantumab§ Sugemalimab Tarextumab§ Tisotumab vedotin Teprotumumab† Tovetumab§ Vantictumab§ Votumumab§ Zalutumumab† Mouse Abagovomab Altumomab pentetate Anatumomab mafenatox Arcitumomab Bectumomab Blinatumomab Capromab pendetide Detumomab Edrecolomab Ibritumomab tiuxetan Igovomab Lilotomab Minretumomab Mitumomab Nacolomab tafenatox Moxetumomab pasudotox Naptumomab estafenatox Oregovomab Pemtumomab† Racotumomab Satumomab pendetide Solitomab Taplitumomab paptox Nofetumomab merpentan Pintumomab Tenatumomab Tositumomab Chimeric Amatuximab§ Bavituximab§ Brentuximab vedotin Carotuximab† Cetuximab Derlotuximab biotin§ Dinutuximab Ecromeximab§ Ensituximab§ Futuximab§ Girentuximab† Indatuximab ravtansine§ Isatuximab Loncastuximab tesirine Margetuximab Mirvetuximab soravtansine Rituximab# Siltuximab Ublituximab Zolbetuximab Humanized Abituzumab§ Alemtuzumab Axatilimab Belantamab mafodotin Bevacizumab Bivatuzumab mertansine§ Brontictuzumab§ Cantuzumab mertansine§ Cantuzumab ravtansine§ Cirmtuzumab Citatuzumab bogatox§ Clivatuzumab tetraxetan Cofetuzumab pelidotin Dacetuzumab§ Demcizumab§ Dalotuzumab§ Datopotamab deruxtecan Denintuzumab mafodotin§ Elotuzumab Emactuzumab Emibetuzumab§ Enoblituzumab§ Epcoritamab Etaracizumab§ Farletuzumab§ Ficlatuzumab§ Flotetuzumab§ Gemtuzumab ozogamicin Glofitamab Imgatuzumab§ Inotuzumab ozogamicin Labetuzumab§ Lifastuzumab vedotin§ Lintuzumab§ Lorvotuzumab mertansine§ Lumretuzumab§ Matuzumab§ Milatuzumab§ Naxitamab Nimotuzumab† Obinutuzumab Ocaratuzumab§ Odronextamab Otlertuzumab§ Onartuzumab§ Oportuzumab monatox† Parsatuzumab§ Pertuzumab Pinatuzumab vedotin§ Polatuzumab vedotin Rosmantuzumab Rovalpituzumab tesirine† Sacituzumab govitecan Sibrotuzumab§ Simtuzumab§ Sofituzumab vedotin§ Tacatuzumab tetraxetan§ Tigatuzumab§ Trastuzumab# (+deruxtecan / +emtansine) Tucotuzumab celmoleukin§ Vandortuzumab vedotin§ Vanucizumab§ Veltuzumab§ Vorsetuzumab mafodotin§ Zenocutuzumab Rat/mouse hybrid Catumaxomab Ertumaxomab§ Chimeric + humanized Depatuxizumab mafodotin† Duvortuxizumab Ontuxizumab§ #WHO-EM ‡Withdrawn from market Clinical trials: †Phase III §Never to phase III No tags for this post. Navigeerimine Tiit RiisaloRaul Kirjanen
